Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28079593 | 0.98 | POLB (0.33) | POLBCA1CA2CA12CA7 | |
| SCHEMBL1927671 | 0.81 | CA2 (0.41) | POLBCA1CA2CA12CA7 | |
| SCHEMBL7335685 | 0.81 | POLB (0.32) | POLBCA1CA2CA12CA7 | |
| SCHEMBL8229612 | 0.78 | CA1 (0.45) | POLBCA1CA2CA12CA7 | |
| SCHEMBL1927669 | 0.77 | POLB (0.31) | POLBCA1CA2CA12CA7 | |
| SCHEMBL1927038 | 0.77 | ALDH1A1 (0.31) | POLBCA1CA2CA12CA7 | |
| SCHEMBL23569219 | 0.74 | CA2 (0.35) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3467639 | 0.73 | MAPT (0.34) | CA1CA2TSHRSMN1; SMN2MMP1 | |
| SCHEMBL27402677 | 0.73 | ALDH1A1 (0.38) | CA1CA2TSHRSMN1; SMN2MMP1 | |
| SCHEMBL18701621 | 0.73 | LMNA (0.32) | CA1CA2TSHRSMN1; SMN2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1665802-A | Bisarylsulfonamide compounds and their use in cancer therapy | CYCLACEL LTD (GB) | 2005-09-07 | — | — | CN | claimed |
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| CN-103224488-A | Heterocyclic compound or salt thereof | OTSUKA PHARMA CO LTD | 2013-07-31 | — | — | CN | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| CN-101842367-A | Heterocyclic compounds and pharmaceutical compositions thereof | OTSUKA PHARMA CO LTD | 2010-09-22 | — | — | CN | disclosed |
| EP-2207773-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-07-21 | — | — | EP | disclosed |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| CN-101547908-A | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-30 | — | — | CN | disclosed |
| CN-101437818-A | Novel Dual Acting Receptor Antagonists (DARA) for AT1 and ETA receptors | TORRENT PHARMACEUTICALS LTD (IN) | 2009-05-20 | — | — | CN | disclosed |
| WO-2009057811-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
| EP-1996588-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | Torrent Pharmaceuticals Ltd (IN) | 2008-12-03 | — | — | EP | disclosed |
| EP-1599477-B1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-30 | — | — | EP | disclosed |
| WO-2007100295-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | TORRENT PHARMACEUTICALS LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
| CN-1665802-A | Bisarylsulfonamide compounds and their use in cancer therapy | CYCLACEL LTD (GB) | 2005-09-07 | — | — | CN | disclosed |
| US-6890956-B2 | Cyclohexyl sulphones as gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2005-05-10 | — | — | US | disclosed |
| US-20040121995-A1 | Cyclohexyl sulphones as gamma-secretase inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | POLB 4006/4885CA1 1390/4885CA2 1345/4885 |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | EDNRA, EDNRB, AGTR1 | POLB 2866/4885CA1 4264/4885CA2 1287/4885 |
| US-20040121995-A1 | Cyclohexyl sulphones as gamma-secretase inhibitors | BACE1, BACE2, APP | POLB 1762/4885CA1 485/4885CA2 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.